Evidence map›Paper›PMID 28356876›Full record

ArticleJournal of medical biochemistry2016

Usefulness of NT-proBNP in the Follow-Up of Patients after Myocardial Infarction.

Mina Radosavljevic-Radovanovic, Nebojsa Radovanovic, Zorana Vasiljevic, Jelena Marinkovic, Predrag Mitrovic, Igor Mrdovic, Sanja Stankovic, Peter Kružliak, Branko Beleslin, Ana Uscumlic and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medical biochemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Biomedicines · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Prognostic value of initial QRS analysis in anterior STEMI: Correlation with left ventricular systolic dysfunction, serum biomarkers, and cardiac outcomes.Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc · 2021
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mina Radosavljevic-RadovanovicCardiology Clinic, Clinical Center of Serbia and Medical School, University of Belgrade.
Nebojsa RadovanovicCardiology Clinic, Clinical Center of Serbia and Medical School, University of Belgrade.
Zorana VasiljevicCardiology Clinic, Clinical Center of Serbia and Medical School, University of Belgrade.
Jelena MarinkovicInstitute of Statistics, Medical School, University of Belgrade, Belgrade, Serbia.
Predrag MitrovicCardiology Clinic, Clinical Center of Serbia and Medical School, University of Belgrade.
Igor MrdovicCardiology Clinic, Clinical Center of Serbia and Medical School, University of Belgrade.
Sanja StankovicCentre of Medical Biochemistry, Clinical Center of Serbia, Belgrade, Serbia.
Peter KružliakInternational Clinical Research Center, St Anne's University Hospital, Brno, Czech Republic.
Branko BeleslinCardiology Clinic, Clinical Center of Serbia and Medical School, University of Belgrade.
Ana UscumlicCardiology Clinic, Clinical Center of Serbia, Belgrade, Serbia.
Jelena KosticCardiology Clinic, Clinical Center of Serbia, Belgrade, Serbia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSince serial analyses of NT-proBNP in patients with acute coronary syndromes have shown that levels measured during a chronic, later phase are a better predictor of prognosis and indicator of left ventricular function than the levels measured during an acute phase, we sought to assess the association of NT-proBNP, measured 6 months after acute myocardial infarction (AMI), with traditional risk factors, characteristics of in-hospital and early postinfarction course, as well as its prognostic value and optimal cut-points in the ensuing 1-year follow-up.

methodsFasting venous blood samples were drawn from 100 ambulatory patients and NT-proBNP concentrations in lithium-heparin plasma were determined using a one-step enzyme immunoassay based on the »sandwich« principle on a Dimension RxL clinical chemistry system (DADE Behring-Siemens). Patients were followed-up for the next 1 year, for the occurrence of new cardiac events.

resultsMedian (IQR) level of NT-proBNP was 521 (335-1095) pg/mL. Highest values were mostly associated with cardiac events during the first 6 months after AMI. Negative association with reperfusion therapy for index infarction confirmed its long-term beneficial effect. In the next one-year follow-up of stable patients, multivariate Cox regression analysis revealed the independent prognostic value of NT-proBNP for new-onset heart failure prediction (p=0.014), as well as for new coronary events prediction (p=0.035). Calculation of the AUCs revealed the optimal NT-proBNP cut-points of 800 pg/mL and 516 pg/mL, respectively.

conclusionsNT-proBNP values 6 months after AMI are mainly associated with the characteristics of early infarction and postinfarction course and can predict new cardiac events in the next one-year follow-up.

Indexed as

myocardial infarctionN-terminal pro-brain natriuretic peptidepostinfarction periodprognostic neurohumoral testing

Identifiers

PMID28356876
PMCPMC5346793

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.